Boehringer Ingelheim

Boehringer Ingelheim is one of the big names in prescription medicines, with a strong presence in human health and animal health rather than a flashy consumer brand. By our assessment, its strength is the depth of a research-led pharmaceutical business that works across multiple therapeutic areas and also runs a serious veterinary line. The downside is the usual one for a large drug maker: long development cycles, heavy regulation, and a business that stays far from everyday visibility. In practice it feels like a classic pharma company, with labs, trials, approvals, and a long tail between discovery and any visible result. Compared with smaller biotech firms, it is less about one dramatic bet and more about a broad, established portfolio. The company is German.